Psilera, a US-based biotechnology company, announced on Tuesday that it has named Magali Haas, MD, PhD as its new director.
Presently, Dr Haas works as founder and chair of Cohen Veterans Bioscience and has earlier served as CEO & president for ten years. She has set up Brain Health Nexus, a global initiative focused on operationalising brain health through the development, validation and adoption of a global brain health index.
Dr Chris Witowski, Psilera CEO, said: "We are thrilled to welcome Magali as an independent member of our board of directors. Her extensive background in neuroscience and experience translating early-stage research and clinical development align perfectly with our mission at Psilera."
SIFI enters scientific collaboration with UCSF on Acanthamoeba Keratitis
Johnson & Johnson's nipocalimab granted FTD for treatment of Sjogren's disease
Vascarta launches phase I VAS101 clinical study in osteoarthritis
GRIN Therapeutics' Radiprodil receives Orphan Drug designation
BioArctic receives US FDA orphan drug designation OOPD for exidavnemab
Physiomics secures GBP102,000 contract with UK biotech for ADC therapy development
Revelation Biosciences reports Gemini's anti-inflammatory potential in PBMC study
Eneboparatide Shows Positive Results in Phase III Trial for Chronic Hypoparathyroidism
Precision BioSciences secures IND clearance for gene editing therapy targeting chronic hepatitis B
Biophytis advances sarcopenia treatment with positive Phase 2 results
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
BioSurfaces collaborates with Morphocell Technologies
iOncologi acquires TargImmune Therapeutics
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results